+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins

Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins

Vaccine 31(1): 219-225

There are a number of related goals of influenza vaccination, including elicitation of protective antibodies and induction of cellular CD4 and CD8+ T cell responses. Because CD4+ T cell expansion and functionality are influenced by peptide specificity and T cell gene expression can be modified by repeated re-stimulations, it is important to evaluate how frequent influenza vaccinations affect CD4+ T cell dependent functions in protective immunity to influenza. Trivalent influenza vaccines (TIV) have production of neutralizing antibodies to HA as their primary goal and main criteria for efficacy. Accordingly, they are not characterized for any other viral components. In the current study, we evaluated whether other influenza virus proteins were present in commercial TIV at levels sufficient for immunogenicity in vivo. Mice that differed with regard to their expressed class II molecules were used in concert with peptide-stimulated cytokine ELISPOT assays to comprehensively evaluate the CD4+ T cell antigen specificity induced by the TIV. Our studies revealed that NA, NP, M1 and NS1 were present in sufficient quantities in the TIV to prime and boost CD4+ T cells. These results suggest that in humans, the broad CD4+ T cell repertoire induced by live infection is continually boosted and maintained throughout life by regular vaccination with licensed intramuscular split vaccines. The implications raised by our findings on CD4+ T cell functionality in influenza are discussed.

(PDF emailed within 0-6 h: $19.90)

Accession: 036629168

Download citation: RISBibTeXText

PMID: 23099328

DOI: 10.1016/j.vaccine.2012.10.039

Related references

Effectiveness of Live Attenuated Influenza Vaccines and Trivalent Inactivated Influenza Vaccines against confirmed Influenza In Children and Adolescents in Saxony-Anhalt, 2012/13. Gesundheitswesen ) 77(7): 499-501, 2016

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 31(5): 770-776, 2013

Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study. Vaccine 35(15): 1856-1864, 2017

Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults. Human Vaccines and Immunotherapeutics 2018: 1-7, 2018

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China. Expert Review of Vaccines 16(11): 1155-1169, 2017

Sub virion influenza vaccines a subunit glyco protein trivalent preparation grippovac se azh for immunization of children and subjects with a chronic pathology against influenza. Vestnik Akademii Meditsinskikh Nauk SSSR (12): 21-29, 1983

T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine. Pediatric Infectious Disease Journal 31(6): E86-E91, 2012

A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. Journal of Infectious Diseases 207(12): 1878-1887, 2013

Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases. Journal of Clinical Microbiology 24(3): 336-342, 1986

Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season. Journal of Infectious Diseases 207(8): 1262-1269, 2013

Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine 11(7): 718-724, 1993

Evaluation of trivalent, live, cold-adapted and inactivated influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A , A , and B viruses. Vaccine 18(9-10): 899-906, Dec 10, 1999

Effectiveness of the 2010 and 2011 Southern Hemisphere trivalent inactivated influenza vaccines against hospitalization with influenza-associated acute respiratory infection among Thai adults aged ≥ 50 years. Influenza and Other Respiratory Viruses 8(4): 463-468, 2015

Serological responses in volunteers to inactivated trivalent subunit influenza vaccine: antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response. Journal of Medical Virology 33(2): 133-137, 1991

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe. Human Vaccines and Immunotherapeutics 12(9): 2259-2268, 2017